Post by Oncology frontier

🎗️🌍 ASCO Spotlight | Professor Thomas Powles on the EV-302 Results That Are Redefining Expectations in Advanced Urothelial Carcinoma At ASCO 2026, Professor Thomas Powles, Global Leading Principal Investigator of the landmark EV-302 trial, presented long-term follow-up data that further solidify enfortumab vedotin plus pembrolizumab (EV+P) as the standard first-line treatment for locally advanced or metastatic urothelial carcinoma. 📖 Read more to explore Professor Powles’ interpretation of the latest EV-302 findings, the evolving role of ADC-immunotherapy combinations, and what these results mean for the future of precision treatment in urothelial carcinoma. #ThomasPowles #ASCO2026 #EV302 #EnfortumabVedotin #Pembrolizumab #UrothelialCarcinoma #ADC #Immunotherapy #Oncology